GALNT11

Across TCGA pan-cancer cohorts, GALNT11 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GALNT11’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where GALNT11 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types GALNT11 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where GALNT11 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GALNT11 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	All	−0.584	<.001	11	view →
HNSC	All	II,III,IV	−0.336	<.001	8	view →
LSCC	All	II,III,IV	−0.229	<.001	7	view →
PDAC	Female	All	−1.189	<.001	6	view →
LUAD	Female	III,IV	+0.288	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

GALNT11–CCRCC

Open the CCRCC breakdown →